Philip J. Facchina, Chief Strategy Officer and Principal of SurgCenter Development, Joins Mesoblast Board

NEXT STORY
SCYNEXIS Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
PREV STORY
TG Therapeutics Completes Rolling Submission of Biologics License Application to the U.S. Food and Drug Administration for Ublituximab in Combination with UKONIQ™(umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Autolus and Moderna sign Option and License Agreement for access to proprietary targeting technology from Autolus

author_avatar
NASDAQ Market News

Motif Bio Presents Iclaprim Data at ESCMID/ASM Conference

Iclaprim overview presented in State of the Art LectureSafety analysis of diabetic patients in ...

author_avatar
NASDAQ Market News

TG Therapeutics Recaps Schedule of Upcoming Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

author_avatar
NASDAQ Market News